中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

13 records (took 0.012 seconds)

    COMBINATIONS OF MDM2 INHIBITORS WITH INHIBITORS OF ERK FOR TREATING CANCERS
    1.
    发明申请
    COMBINATIONS OF MDM2 INHIBITORS WITH INHIBITORS OF ERK FOR TREATING CANCERS 审中-公开

    公开(公告)号：US20200281910A1

    公开(公告)日：2020-09-10

    申请号：US16754539

    申请日：2018-10-11

    Applicant: NOVARTIS AG

    Inventor： Giordano Caponigro ,  Ensar Halilovic ,  Kelli-Ann Monaco

    IPC: A61K31/4439 ,  A61K31/4965 ,  A61P35/00

    Abstract: The present invention relates to a pharmaceutical combination comprising (a) an MDM2 inhibitor and (b) an ERK inhibitor, for use in the treatment of a cancer. This invention relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination; and kits and/or packages containing such combinations.

    PHARMACEUTICAL COMBINATIONS
    2.
    发明申请
    PHARMACEUTICAL COMBINATIONS 审中-公开

    公开(公告)号：US20180193346A1

    公开(公告)日：2018-07-12

    申请号：US15914479

    申请日：2018-03-07

    Applicant: Novartis AG

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/506 ,  A61K31/496

    CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

    Pharmaceutical combinations and their use
    4.
    发明申请
    Pharmaceutical combinations and their use 审中-公开

    公开(公告)号：US20200246331A1

    公开(公告)日：2020-08-06

    申请号：US16535214

    申请日：2019-08-08

    Applicant: Novartis AG

    Inventor： Ensar Halilovic ,  Caroline Emery

    IPC: A61K31/496 ,  A61K45/06 ,  A61K31/517 ,  A61K31/497 ,  A61P35/00 ,  A61K31/506

    Abstract: The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (a) a MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof and a PKC pathway inhibitor of formula III, formula IV, formula V or formula VI or a pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carriers and related disclosure embodiments. The disclosure further relates to use of an MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof, alone for use in the treatment of a proliferative disease.

    Pharmaceutical combinations and their use
    5.
    发明申请
    Pharmaceutical combinations and their use 审中-公开

    公开(公告)号：US20180243293A1

    公开(公告)日：2018-08-30

    申请号：US15751954

    申请日：2016-08-11

    Applicant: Novartis AG

    Inventor： Ensar Halilovic ,  Caroline Emery

    IPC: A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/497 ,  A61P35/00

    CPC classification number: A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K45/06 ,  A61P35/00 ,  A61K2300/00

    Abstract: The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (a) a MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof and a PKC pathway inhibitor of formula III, formula IV, formula V or formula VI or a pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carriers and related disclosure embodiments. The disclosure further relates to use of an MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof, alone for use in the treatment of a proliferative disease.

    Pharmaceutical combinations
    7.
    发明授权
    Pharmaceutical combinations 有权

    公开(公告)号：US10220038B2

    公开(公告)日：2019-03-05

    申请号：US15914479

    申请日：2018-03-07

    Applicant: Novartis AG

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/4188 ,  A61K31/505 ,  A61K31/496 ,  A61K31/506

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

    PHARMACEUTICAL COMBINATIONS
    8.
    发明申请
    PHARMACEUTICAL COMBINATIONS 审中-公开

    公开(公告)号：US20180015092A1

    公开(公告)日：2018-01-18

    申请号：US15683887

    申请日：2017-08-23

    Applicant: Novartis AG

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/506 ,  A61K31/496

    CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

    Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
    9.
    发明授权
    Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers 有权

    公开(公告)号：US11406627B2

    公开(公告)日：2022-08-09

    申请号：US16754539

    申请日：2018-10-11

    Applicant: NOVARTIS AG

    Inventor： Giordano Caponigro ,  Ensar Halilovic ,  Kelli-Ann Monaco

    IPC: A61K31/4439 ,  A61P35/00 ,  A61K31/4965

    Abstract: The present invention relates to a pharmaceutical combination comprising (a) an MDM2 inhibitor and (b) an ERK inhibitor, for use in the treatment of a cancer. This invention relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination; and kits and/or packages containing such combinations.

    PHARMACEUTICAL COMBINATIONS
    10.
    发明申请
    PHARMACEUTICAL COMBINATIONS 审中-公开

    公开(公告)号：US20190160069A1

    公开(公告)日：2019-05-30

    申请号：US16263517

    申请日：2019-01-31

    Applicant: Novartis AG

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/506 ,  A61K31/4188 ,  A61K31/505 ,  A61K31/496

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Patent Agency Ranking